News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ensemble Therapeutics Corporation Receives Two Notices of Allowance for Fundamental Patents to DNA-Programmed Chemistry Process for Novel Macrocycle Therapeutics



7/6/2011 10:57:13 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing Ensemblins™, a novel class of small molecule therapeutics with the power of biologics, today announced that the US Patent and Trademark Office (USPTO) has issued two Notices of Allowance relating to patents licensed exclusively by Harvard University to Ensemble. These newly allowed claims encompass broad and fundamental aspects of DNA-Programmed Chemistry (DPC) molecular library construction, affirming Ensemble’s novel and proprietary approach to building diverse libraries of molecules for drug discovery.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES